Assessing a peptidylic inhibitor-based therapeutic approach that simultaneously suppresses polyglutamine RNA- and protein-mediated toxicities in patient cells and Drosophila
Polyglutamine (polyQ) diseases represent a group of progressive neurodegenerative disorders that are caused by abnormal expansion of CAG triplet nucleotides in disease genes. Recent evidence indicates that not only mutant polyQ proteins, but also their corresponding mutant RNAs, contribute to the pa...
Main Authors: | Qian Zhang, Ho Tsoi, Shaohong Peng, Pan P. Li, Kwok-Fai Lau, Dobrila D. Rudnicki, Jacky Chi-Ki Ngo, Ho Yin Edwin Chan |
---|---|
Format: | Article |
Language: | English |
Published: |
The Company of Biologists
2016-03-01
|
Series: | Disease Models & Mechanisms |
Subjects: | |
Online Access: | http://dmm.biologists.org/content/9/3/321 |
Similar Items
-
Cognitive Changes in the Spinocerebellar Ataxias Due to Expanded Polyglutamine Tracts: A Survey of the Literature
by: Evelyn Lindsay, et al.
Published: (2017-07-01) -
Polyglutamine-expanded ataxin-3 activates mitochondrial apoptotic pathway by upregulating Bax and downregulating Bcl-xL
by: An-Hsun Chou, et al.
Published: (2006-02-01) -
Ubiquitin-binding site 1 of pathogenic ataxin-3 regulates its toxicity in Drosophila models of Spinocerebellar Ataxia Type 3
by: Matthew V. Prifti, et al.
Published: (2023-01-01) -
New Perspectives of Gene Therapy on Polyglutamine Spinocerebellar Ataxias: From Molecular Targets to Novel Nanovectors
by: Fabiola V. Borbolla-Jiménez, et al.
Published: (2021-07-01) -
Population genetics of spinoсerebellar ataxias caused by polyglutamine expansions
by: A. N. Shuvaev, et al.
Published: (2019-07-01)